An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1465-542X
Umfang
Online-Ressource
Sprache
Englisch
Anmerkungen
online resource.

Erschienen in
An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer ; volume:23 ; number:1 ; day:4 ; month:3 ; year:2021 ; pages:1-12 ; date:12.2021
Breast cancer research ; 23, Heft 1 (4.3.2021), 1-12, 12.2021

Urheber
Stringer-Reasor, Erica M.
May, Jori E.
Olariu, Eva
Caterinicchia, Valerie
Li, Yufeng
Chen, Dongquan
Della Manna, Deborah L.
Rocque, Gabrielle B.
Vaklavas, Christos
Falkson, Carla I.
Nabell, Lisle M.
Acosta, Edward P.
Forero-Torres, Andres
Yang, Eddy S.
Beteiligte Personen und Organisationen
SpringerLink (Online service)

DOI
10.1186/s13058-021-01408-9
URN
urn:nbn:de:101:1-2021041814365191621257
Rechteinformation
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
14.08.2025, 10:46 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

  • Stringer-Reasor, Erica M.
  • May, Jori E.
  • Olariu, Eva
  • Caterinicchia, Valerie
  • Li, Yufeng
  • Chen, Dongquan
  • Della Manna, Deborah L.
  • Rocque, Gabrielle B.
  • Vaklavas, Christos
  • Falkson, Carla I.
  • Nabell, Lisle M.
  • Acosta, Edward P.
  • Forero-Torres, Andres
  • Yang, Eddy S.
  • SpringerLink (Online service)

Ähnliche Objekte (12)

Metastatic Triple-Negative Breast Cancer

Metastatic Triple-Negative Breast Cancer

Updated Austrian treatment algorithm for metastatic triple-negative breast cancer

Updated Austrian treatment algorithm for metastatic triple-negative breast cancer

Metastatic and triple-negative breast cancer: challenges and treatment options

Metastatic and triple-negative breast cancer: challenges and treatment options

Practical consensus recommendations on management of triple-negative metastatic breast cancer

Practical consensus recommendations on management of triple-negative metastatic breast cancer

SABCS 2020: update on triple-negative and metastatic HER2-positive breast cancer

SABCS 2020: update on triple-negative and metastatic HER2-positive breast cancer

PI3K inhibition circumvents resistance to SHP2 blockade in metastatic triple-negative breast cancer

PI3K inhibition circumvents resistance to SHP2 blockade in metastatic triple-negative breast cancer

The Gαh-PLCδ1 signaling axis drives metastatic progression in triple-negative breast cancer

The Gαh-PLCδ1 signaling axis drives metastatic progression in triple-negative breast cancer

Feasibility study of personalized peptide vaccination for metastatic recurrent triple-negative breast cancer patients

Feasibility study of personalized peptide vaccination for metastatic recurrent triple-negative breast cancer patients

CK2α-mediated phosphorylation of GRP94 facilitates the metastatic cascade in triple-negative breast cancer

CK2α-mediated phosphorylation of GRP94 facilitates the metastatic cascade in triple-negative breast cancer

Ebastine impairs metastatic spread in triple-negative breast cancer by targeting focal adhesion kinase

Ebastine impairs metastatic spread in triple-negative breast cancer by targeting focal adhesion kinase

WNT10B/β‐catenin signalling induces HMGA2 and proliferation in metastatic triple‐negative breast cancer

WNT10B/β‐catenin signalling induces HMGA2 and proliferation in metastatic triple‐negative breast cancer

A plasma SNORD33 signature predicts platinum benefit in metastatic triple-negative breast cancer patients

A plasma SNORD33 signature predicts platinum benefit in metastatic triple-negative breast cancer patients

Verbundene Objekte